Lang Juan, Xiong Zhongkui
Department of Pathology, Shaoxing People's Hospital, Shaoxing, Zhejiang, China.
Department of Medical Imaging, School of Medicine, Shaoxing University, Shaoxing, Zhejiang, China.
Front Cell Dev Biol. 2025 Aug 7;13:1631652. doi: 10.3389/fcell.2025.1631652. eCollection 2025.
Parkinson's disease (PD) is the most prevalent age-related neurodegenerative motor disorder. It affects approximately 1% of individuals aged 65 and older, with its prevalence increasing significantly with advancing age. Current therapeutic approaches primarily focus on symptom management and modestly slowing disease progression, while definitive interventions capable of halting or reversing neurodegeneration remain unavailable. Emerging studies suggest that misfolded proteins progressively accumulate in the neurodegenerating brain, partially attributable to elevated levels of reactive oxygen species and reactive nitrogen species (RNS). The RNS family includes various nitrogen-based compounds, such as nitric oxide (NO), nitroxyl derivatives, and S-nitrosothiol modifications. Phytochemicals have attracted considerable scientific interest as promising candidates for disease-modifying therapies. Prior studies have shown that paederosidic acid, extracted from (Lour.) Merrill, exhibits notable neuroprotective properties in rodent models. However, the potential of paederoside to confer protection in PD cellular models remains unexplored.
Paederoside, a bioactive compound isolated from (Rubiaceae family), including and , was evaluated using rotenone-challenged Neuro-2A (N2A) cells and BV-2 microglial cultures, which served as experimental models of PD pathology. Catalpol was used as a comparative pharmacological reference.
In this study, both paederoside and paederosidic acid methyl ester (PAME) significantly reduced NO accumulation in rotenone-induced N2A and BV-2 cells. Paederoside induced a dose-dependent reduction in inducible nitric oxide synthase (iNOS) activity in the rotenone-treated BV-2 cells. When the nuclear factor-κB (NF-κB) inhibitor BAY11-7082 was added 2 h before rotenone exposure, no statistically significant difference in NO levels was observed between the paederoside-treated and untreated groups. Pretreatment with 1 μM or 10 μM of paederoside significantly attenuated the formation of nitrated α-synuclein (α-Syn) in response to rotenone exposure. Furthermore, pretreatment with 10 μM paederoside markedly enhanced cell viability in rotenone-treated N2A cells.
In summary, these findings demonstrate the neuroprotective potential of paederoside through modulation of the NF-κB/NOS/NO/nitrated α-Syn nitration signaling pathway.
帕金森病(PD)是最常见的与年龄相关的神经退行性运动障碍。它影响约1%的65岁及以上人群,且患病率随年龄增长显著增加。目前的治疗方法主要集中在症状管理和适度减缓疾病进展,而能够阻止或逆转神经退行性变的确定性干预措施仍然不可用。新出现的研究表明,错误折叠的蛋白质在神经退行性变的大脑中逐渐积累,部分原因是活性氧和活性氮(RNS)水平升高。RNS家族包括各种含氮化合物,如一氧化氮(NO)、硝酰基衍生物和S-亚硝基硫醇修饰。植物化学物质作为有前景的疾病修饰疗法候选物引起了相当大的科学关注。先前的研究表明,从白花蛇舌草(Lour.)Merrill中提取的去乙酰车叶草苷酸在啮齿动物模型中表现出显著的神经保护特性。然而,车叶草苷在PD细胞模型中的保护潜力仍未被探索。
车叶草苷是从茜草科植物白花蛇舌草(包括Hedyotis diffusa Willd.和Oldenlandia diffusa (Willd.) Roxb.)中分离出的一种生物活性化合物,使用鱼藤酮诱导的Neuro-2A(N2A)细胞和BV-2小胶质细胞培养物作为PD病理学的实验模型对其进行评估。梓醇用作比较药理学参考。
在本研究中,车叶草苷和去乙酰车叶草苷酸甲酯(PAME)均显著降低了鱼藤酮诱导的N2A和BV-2细胞中NO的积累。车叶草苷在鱼藤酮处理的BV-2细胞中诱导了诱导型一氧化氮合酶(iNOS)活性的剂量依赖性降低。当在鱼藤酮暴露前2小时加入核因子κB(NF-κB)抑制剂BAY11-7082时,车叶草苷处理组和未处理组之间的NO水平未观察到统计学上的显著差异。用1μM或10μM车叶草苷预处理可显著减弱鱼藤酮暴露后硝化α-突触核蛋白(α-Syn)的形成。此外,用10μM车叶草苷预处理可显著提高鱼藤酮处理的N2A细胞的活力。
总之,这些发现证明了车叶草苷通过调节NF-κB/NOS/NO/硝化α-Syn硝化信号通路具有神经保护潜力。